{Reference Type}: Journal Article
{Title}: Updates in the Management of Giant Cell Arteritis.
{Author}: Baig A;Gafoor-Haseeb S;Goldsher J;Siddique F;
{Journal}: Curr Neurol Neurosci Rep
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 24
{Factor}: 6.03
{DOI}: 10.1007/s11910-024-01348-9
{Abstract}: <B>OBJECTIVE: </B>To briefly review the latest updates in management in giant cell arteritis, an autoimmune vasculitis affecting the medium to large vessels.<BR><B>RESULTS: </B>Here, we review the known and newer trends in management of giant cell arteritis. While high dose glucocorticoids remain the mainstay of therapy, immunosuppressive medications are increasingly utilized to reduce the burden and risk of long-term glucocorticoid use. Published guidelines by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) suggest early use of steroid-sparing immunosuppressive medications in patients with recently diagnosed or relapsing giant cell arteritis. Immunosuppressive medications include oral small molecules such as methotrexate and leflunomide and biologics, including the recently Federal Drug Administration (FDA) approved tocilizumab. Glucocorticoids remain the cornerstone of management for newly diagnosed disease but with the increasing use of medications such as IL-6 inhibitors, patients are decreasing steroid use within weeks, thereby limiting risks associated with long-term steroid use.